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Abstract
Past studies have shown that carbohydrate residues reactive with the Griffonia simplicifolia isolectin B4 (GS I-B4) are
present on the surface of highly-malignant murine sarcoma cells but are lacking or expressed in much lower amounts on
the surface of low-malignant cells isolated from the same parent tumors (Am J Pathol 111: 27; J Nat Cancer Inst 71:
1281). In the present study it is shown that an antibody which recognizes the trisaccharide Galα1-3Galβ1-4GlcNAc- is
reactive with the highly-malignant cells but is non-reactive with the low-malignant cells. Further studies show that the high-
malignant cells not only bind GS I-B4 but also bind Evonymus europaea lectin (which like GS I-B4 recognizes terminal
galactose in α1-3 linkage) and Erythina crystagalli lectin (which recognizes sub-terminal galactose in the β1-4 linkage
– e.g., Galβ1-4GlcNAc). In contrast, the low malignant cells bind Erythina crystagalli lectin as efficiently as the high
malignant cells but do not bind (or bind much smaller amounts of) either GS I-B4 or Evonymus europaea lectin. The
present studies also show that there is no significant difference between high- and low-malignant cells in expression of α-
galactosidase activity. In contrast, the high-malignant cells express high levels of α-galactosyl transferase activity while this
enzyme is virtually undetectable in low-malignant cells. Taken together, these studies indicate that differential expression of
a single monosaccharide residue distinguishes high- and low-malignant murine sarcoma cells. These studies also identify a
mechanism to account for surface carbohydrate differences between the high- and low-malignant cells.
Introduction
In previous studies we established a series of high-malignant
and low-malignant cell lines from a number of different
carcinogen-induced murine sarcomas [1, 2]. Among these
tumor cell lines there was a 100% correlation between ca-
pacity of the cell lines to bind Griffonia simplifolia isolectin
B4 (GS I-B4) and capacity to form metastatic tumors in
syngeneic mice [2, 3]. GS I-B4 recognizes carbohydrate
structures that terminate in α-D-galacosyl residues (αGal)
linked to its sub-terminal sugar [4]. Although GS I-B4 is not
completely specific for αGal, this monosaccharide is one
of the preferred ligands [4]. Following our initial observa-
tions with the murine sarcoma cells, Grimstad and Bosnes
extended these findings to other murine tumor lines [5].
Additionally, Castronovo et al. showed that a naturally oc-
curring antibody which recognizes αGal not only reacted
with murine MO4 cells, but also inhibited lung colonization
by intravenously-injected MO4 cells [6].
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Terminal αGal expression is rare in primates [7]. It is of
interest, therefore, that this epitope has been detected on the
surface of a number of human tumor lines including those
derived from breast epithelium [8–10]. Consistent with this,
it was shown by Petryniak et al. that human breast cancer
cells but not normal breast epithelial cells are reactive with
GS I-B4 [11]. Since expression of epitopes that are reactive
with GS I-B4 is correlated with malignant potential in both
rodents and humans, efforts to delineate the structural basis
for lectin reactivity and efforts to understand how expression
of these epitopes is regulated seem warranted. These issues
are addressed in the present report.
Materials and methods
Cells
High- and low-malignant murine tumor cell lines were es-
tablished from three different methylchonanthrene-induced
sarcomas in C57bl/6 mice [1, 2]. The high-malignant cells
were designated as 1.0, 1.1 and 1.2, respectively, while
their counterpart low-malignant cells were designated as
1.0/anti-Br, 1.1/anti-Br and 1.2/anti-Br respectively. Anti-Br
connotes resistance to lysis in the presence of complement
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and antibodies to the human blood group B antigen [3]. For
present studies, all of the cell lines were grown in mono-
layer culture using Minimal Essential Medium of Eagle with
Earl’s salts supplemented with non-essential amino acids
(MEM) and 10% fetal bovine serum (MEM-FBS) as cul-
ture medium. Cells were grown at 37 ◦C and 5% CO2 and
sub-cultured as required.
Monoclonal antibody
We previously reported on the preparation of a monoclonal
antibody which recognizes the epitope: Galα1-3Galβ1-
4GlcNAc- [12]. In brief, plasma membrane glycoproteins
from Ehrlich ascites tumor cells were isolated and used to
immunize BALB/c mice. Cell fusion was carried out ac-
cording to the methods of Galfre et al. and McKearn [13,
14]. Clones were screened by enzyme-linked immunosor-
bant assay with Galα1-3Galβ1-4GlcNAc-bovine serum al-
bumin and Galα1-3Galβ1-4GlcNAc-bovine thyroglobulin
as substrates. Only clones reactive with both substrates
were expanded and subcloned. Stable cultures of antibody-
producing cells were eventually obtained and monoclonal
antibody was produced from these cells in pristane-treated
BALB/c mice. The monoclonal antibody was purified
by chromatography on a Galα1-3Galβ1-4GlcNAc-Synsorb
affinity column.
Monoclonal antibody staining
Each of the cell lines was stained with the monoclonal an-
tibody. To 50 µl of a suspension of washed cells in PBS
containing 5% fetal bovine serum (PBS-FBS) was added
50 µl of the monoclonal antibody solution at 5 µg/ml in
PBS. Normal mouse IgM was used at the same concentra-
tion as a control. After incubation for 30 min, the cells were
washed and stained with 50 µl of FITC-coupled anti-mouse
Ig(G+M) antibody (Boehringer Mannheim, Indianapolis,
Indiana). The cells were then washed exhaustively in PBS-
FBS and finally resuspended in the same buffer. They were
examined by fluorescence microscopy and photographed.
Lectin staining
Lectin-staining was carried out with each of the cell
lines. Lectins used included GS I-B4, Evonymus europaea
lectin and Erythina cyrystagalli lectin. The three lectins
were obtained commercially (Sigma Chemical Co., St.
Louis, Missouri and E-Y Laboratories, San Mateo, Cal-
ifornia) as fluorescein isothiocyanate (FITC) conjugates.
Specific carbohydrate inhibitors for each of the sugars
were also obtained from commercial sources. These in-
clude methyl α-D-galactopyranoside (10 mM) for GS I-B4,
N-acetyllactosamine (10 mM) for Erythina crystagalli and
lactose (100 mM) for Evonymus europaea.
Cells in suspension after removal from the substratum
by brief trypsinization were stained with each of the lectins.
Briefly, 250,000 cells were mixed with 10 µg of the FITC-
labeled lectins in a total volume of 150 µl of PBS. When
inhibitors were present, they were added at a final concen-
tration of 10–100 mM. After incubation for 45 min at room
temperature, cells were separated from the unbound lectin,
washed two times in PBS and fixed in 2% paraformaldeyde.
The stained cells were then analyzed by flow cytometry.
Routinely, 10,000 cells were analyzed per group.
α-Galactosidase treatment
In certain experiments, cells were exposed to green coffee
bean α-galactosidase (Worthington Chemicals Corporation;
Freehold, New Jersey) prior to staining. For this, 1.2 units of
enzyme was incubated for three hours with 2,000,000 cells
in a final volume of 0.5 ml. MEM-FBS was used as incuba-
tion buffer. After enzyme treatment, the cells were washed
and stained as described above.
Galactosyl transferase measurement
Cell extracts were prepared from each of the high and low
malignant cells and standardized with regard to protein con-
centration. Extracts were assayed for galactosyl transferase
activity using transfer of UDP-14C-galactose to asialo-
orosomucoid as the galactose acceptor. Asialo-orosomucoid
was used as the acceptor because olgiosaccharides of this
glycoprotein terminate in Galα1-4GlcNAc. This disaccha-
ride can accept D-galactose in the α position only. The
reaction mixture (100 µl final volume) contained 20 mM
HEPES, pH 6.2, 10 mM MnCl2, 38 µg of cross-linked
asialo-orosomucoid, 0.1 µCi UDP-14C-galactose, 0.2%
β-mercaptoethanol and varying amounts of cell lysates.
[Cross-linked asialo-orosomucoid was prepared by mixing
5 ml of 0.1 M 1-ethyl-3-[3-dimethylaminopropyl] carbodi-
imide (EDC) (Pierce Chemical Company, Rockford, Illi-
nois) containing 5 mM sulfo-N-hydroxysuccinamide (sulfo-
NHS) with 26.7 mg of asialo-orosomucoid at pH 8.5. After
incubation for 15 h at 37 ◦C, the mixture was dialyzed
exhaustively against water and then lyophilized until use.]
The mixture for galactosyl transferase measurement was
incubated for one hour at 37 ◦C. The reaction was ter-
minated by adding 100 µl of 4% phosphotungstic acid
in 20% trichloroacetic acid and incubation for 15 min in
the cold. The precipitate which formed was centrifuged
in a microfuge at maximal speed for 5 min, washed two
times with 2% phosphotungstic acid in 10% trichloroacetic
acid and solubilized in 350 µl of 1N NaOH for 2 h at
37 ◦C. The solution was then counted for total radioactivity
by liquid scintillation. Controls included mixtures with-
out cell extracts and mixtures without cross-linked asialo-
orosomucoid. Values obtained in control samples without
cell extracts were routinely less than 50 counts per minute
while values obtained in the presence of cell extracts but
without the asialo-orosomucoid were up to 1500 counts per
minute.
Northern blot analysis for α1-3 galactosyl transferase
mRNA
Total cellular RNA was extracted from one set of high and
low malignant cells (1 × 107 1.0 and 1.0/anti-Br cells) ac-
cording to the procedure of Chirgwin et al. [41]. After
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fractionation on a denaturing 1% formaldehyde-agarose gel,
RNA was hybridized with 32P-labeled pCDM7-murine α1-3
galactosyltransferase cDNA at high stringency. The murine
α1-3 galactosyltransferase cDNA probe was a generous gift
from Dr John Lowe (Department of Pathology, University of
Michigan) [15].
Galactosidase measurement
Extracts prepared from each of the high and low malig-
nant cells were assayed for α-galactosidase activity. The
p-nitrophenyl derivative of α-D-galactopyranoside was used
as substrate and the assay was conducted as described pre-
viously [1, 16]. Briefly, this involved incubation of the
substrate with the extract for 1 h at 37 ◦C and pH 4.3. At
the end of the incubation period, the sample was brought
to pH 10.4 with 0.4 N glycine-NaOH buffer and the yellow
color which developed at alkaline pH quantified spectropho-
tometrically at 405 nm. Preliminary experiments indicated
that measurements made at one hour of incubation were on
the linear portion of the enzyme activity curve.
Results
Reactivity of the high- and low-malignant murine sarcoma
cells with an anti-trisaccharide monoclonal antibody
In the first series of experiment, the three high-malignant
cell lines and three low-malignant cell lines were examined
for reactivity with a monoclonal anti-trisaccharide antibody.
Immunofluorescence photographs of one pair of high- and
low-malignant cell lines (1.0 and 1.0/anti-Br cells) are shown
in Figure 1. The high malignant cells (1.0) shown in the
left-panels were reactive with the anti-trisaccharide antibody
(C) while the low malignant cells (1.0/anti Br) (right pan-
els) demonstrated much less staining (D). The other two
pairs of tumor lines were identical to the 1.0 and 1.0/anti-
Br cells. None of the cells showed significant reactivity with
the control IgM antibody (Figures 1A and B).
Lectin-reactivity of high and low malignant cells
The same three pairs of high-malignant and low-malignant
cell lines were next examined for reactivity with a panel of
lectins. Histograms of one pair of high- and low-malignant
cell lines (1.0 and 1.0/anti-Br cells) are shown in Figure 2.
The high-malignant (1.0) cells were reactive with all three
lectins while the low malignant (1.0/anti-Br) cells demon-
strated much less reactivity with GS I-B4 and Evonymus
europaea lectin than did the high-malignant cells. In con-
trast, high- and low-malignant cells were equally reactive
with Erythina crystagalli lectin. Data from all three pairs
of cell lines were consistent with the findings presented in
Figure 2, and these data are summarized in Table 1.
Effects of α-galactosidase treatment on lectin reactivity
High malignant cells (1.0) were exposed to green coffee
bean α-galactosidase as described in the ‘Materials and
Table 1. Lectin-reactivity of high and low malignant murine fi-
brosarcoma cells.
Mean channel number
Cell line GS I-B4 Evonymus Erythina
europaea crystagalli
1.0
No lectin 5 4 3
Lectin 3919 327 326
Lectin + inhibitor 266 13 103
1.0/anti-Br
No lectin 6 7 6
Lectin 120 17 861
Lectin + inhibitor 69 7 208
1.1
No lectin 4 5 4
Lectin 707 160 1194
Lectin + inhibitor 452 43 –
1.1/anti-Br
No lectin 4 5 6
Lectin 24 11 850
Lectin + inhibitor 10 8 190
1.2
No lectin 5 5 5
Lectin 1227 263 324
Lectin + inhibitor 84 44 97
1.2/anti-Br
No lectin 4 5 4
Lectin 17 10 642
Lectin + inhibitor 10 8 450
Cells were treated with FITC-labeled lectins as described in the
‘Materials and methods’ section and examined by flow cytom-
etry. Values shown represent mean channel fluorescence based
on 10,000 independent measurements. ‘No lectin’ control rep-
resents background autofluorescence. ‘Lectin’ alone represents
total fluorescence and ‘Lectin + inhibitor’ represents non-specific
fluorescence. Inhibitor for GS I-B4 was 10 mM methyl α-D-
galactopyranoside; Inhibitor for Evonymus europaea was 100 mM
lactose and inhibitor for Erythina crystagalli was 10 mM N-
acetyllactosamine. Each cell line was examined on three or more
occasions with similar results.
methods’ section. Exposure of the cells to the enzyme for
one hour under conditions which were non-toxic to the cells
resulted in the loss of virtually 100% of the staining with
GS I-B4 (Figure 3). Staining with Evonymus europaea was
also reduced following α-galactosidase treatment, but this
treatment had no effect on Erythina crystagalli staining (not
shown). Taken together with lectin- and antibody-staining
data, these findings suggest that the high malignant cells
express the trisaccharide Galα1-3Galβ1-4GlcNAc- on their
surface. Further, these studies suggest that only the terminal
monosaccharide unit (αGal) is missing on the low malignant
cells, while there appears to be little difference in expres-
sion of subterminal Gal β1-4GlcNAc- between the high- and
low-malignant cells.
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Figure 1. Detection of Gal α1-3 Gal β1-4 GlcNAc- on high-malignant and low-malignant murine fibrosarcoma cells by indirect immunofluorescence.
Tumor cells were stained in suspension as described in the ‘Materials and methods’ section. Immunofluorescence photomicrographs of (A) high-malignant
(1.0) cells and (B) low-malignant (1.0/anti-Br) cells stained with control IgM. Immunofluorescence photomicrographs of (C) high-malignant (1.0) cells
and (D) low-malignant (1.0/anti-Br) cells stained with anti-trisaccharide antibody.
Figure 2. Flow cytometric analysis of high malignant (1.0) cells and low malignant (1.0/anti-Br) cells after staining with GS I-B4, Evonymus europea
and Erythina crystagalli lectins. Lectin staining in the absence and presence of the respective inhibitors was carried out as described in the ‘Materials and
methods’ section. With each lectin, the upper panel represents background staining (no lectin present); the middle panel represents total staining (lectin but
no inhibitor) and the lower panel represents non-specific staining (lectin + inhibitor). Each cell line was examined on at least two occasions with similar
results.
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Figure 3. Effects of α-galactosidase treatment on binding of GS I-B4 to high-malignant (1.0) sarcoma cells by indirect immunofluorescence. The upper
(left) panel shows control 1.0 cells stained with GS I-B4. The middle panel shows 1.0 cells following treatment with green coffee bean α-galactosidase and
then stained with GS I-B4. The lower panel shows control low-malignant (1.0/anti-B
r) cells stained with GS I-B4. Right-side panels show corresponding
phase-contrast photomicrographs.
α-Galactosidase activity in extracts of high and low
malignant cells
Since it appeared from the above studies that only the
terminal αGal was lacking on the low malignant cells, exper-
iments were conducted to determine the reason for the lack
of expression on these cells. Extracts were prepared from
all six cell lines and assessed for α-galactosidase activity as
described in the ‘Materials and methods’ section. The results
(Table 2) indicate that although there were differences in
total activity among the three pairs of lines, there was no
significant difference between the high-malignant line and
low-malignant line from any of the three tumors.
Galactosyl transferase activity in extracts of high and low
malignant cells
Extracts were prepared from all six cell lines and assessed
for galactosyl transferase activity as described in the Mate-
rials and methods section. The results (Table 3) show that
Table 2. α-galactosidase activity in extracts of
high and low malignant murine fibrosarcoma cells.
Enzyme activity
Cell line ( O.D.405 per 100 µg protein)
1.0 0.49 ± 0.01
1.0/anti-Br 0.59 ± 0.01
1.1 0.49 ± 0.01
1.1/anti-Br 0.50 ± 0.04
1.2 0.68 ± 0.02
1.2/anti-Br 0.53 ± 0.02
α-Galactosidase activity was assessed as described
in the ‘Materials and methods’ section using the
p-nitrophenyl derivative of α-D-galactopyranoside
as substrate. Values shown are means and stan-
dard deviations based on triplicate samples in a
single experiment. Each cell line was assayed two
separate times with similar results.
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Table 3. Galactosyl transferase activity in extracts of high
and low malignant murine fibrosarcoma cells.
Enzyme activity
Cell line (CPM of UDP-14C-galactose transferred)
1.0 3005 ± 289
1.0/anti- Br 142 ± 17
1.1 2332 ± 70
1.1/anti-Br 0
1.2 2391 ± 144
1.2/anti-Br 808 ± 43
Galactosyl transferase activity was assessed as described in
the ‘Materials and methods’ section. Values shown are means
and standard deviations based on triplicate samples in a sin-
gle experiment. Each cell line was assayed two separate times
with similar results. When cell extracts were omitted from the
reaction mixture, less than 50 CPM of UDP-14C-galactose
was transferred. This values has not been subtracted from
the values shown in the table. When asialoorosomucoid was
omitted from the reaction mixture, 1505 ± 95 CPM was
transferred. This values has been subtracted from the values
shown in the table.
galactosyl transferase activity was much higher in each of
the three high-malignant cell lines than in the corresponding
low-malignant lines. The galactose acceptor used in these
experiments, asialo-orosomucoid, is known to bind galac-
tose in the α1-3 linkage [17]. It is possible, however, that
not all of the 14C-galactose bound to the acceptor was in
this linkage. In order to demonstrate that at least some of
the galactose bound to asialo-orosomucoid was in the α1-3
linkage, an extract prepared from the 1.0 (high-malignant)
cell line was used to catalyze the transfer of 14C-galactose
to asialo-orosomucoid. Following transfer of the galactose
to the asialo-orosomucoid, the galacose-bound acceptor was
exposed to green coffee bean α-galactosidase. Following en-
zyme exposure, released radioactivity was separated from
the acceptor and analyzed. A significant portion (i.e., ap-
proximately 16%) of the originally bound 14C-galactose was
released from the acceptor with this treatment. While this
enzyme digestion procedure undoubtedly underestimates the
amount of 14C-galactose specifically linked to the subtermi-
nal galactose through the α1-3 linkage, it demonstrates that
some of it is.
mRNA levels for α1-3 galactosyl transferase in high and
low malignant cells
In a final series of experiments, RNA was prepared from 1.0
and 1.0/anti-Br cells, separated by agarose-gel electrophore-
sis and blotted with radiolabeled (α1-3)GT cDNA insert as
a probe for α1-3 galactosyl transferase mRNA. A single, in-
distinguishable band of approximately 4.15 kb in size was
identified in both the high- and low-malignant cells (Fig-
ure 4), suggesting equal amounts of steady-state message for
the α1-3-galactosyltransferase.
Figure 4. Northern blot analysis of RNA isolated from 1.0 and 1.0/anti-Br
cells. Total RNA (15 µg/lane) was fractionated on a 1.4% formaldehyde
agarose gel and transferred to a nitrocellulose membrane. The α1-3 galac-
tosyl transferase transcript (4.15 kb) was detected by hybridization with a
32P-labeled (α1-3)GT cDNA insert.
Discussion
There is a strong correlation between cell surface expression
of GS I-B4-reactive carbohydrate moieties and malignant
potential among murine sarcomas [2, 3, 5, 6]. This report
presents evidence that the moiety responsible for lectin reac-
tivity is the trisaccharide, Galα1-3Galβ1-4GlcNAc-. This is
based on a correlation between reactivity of GS I-B4-positive
cells with a monoclonal antibody which is highly specific
for the trisaccharide structure Galα1-3Galβ1-4GlcNAc- and
lack of reactivity of GS I-B4-negative cells with the same an-
tibody. This monoclonal antibody does not react with a num-
ber of closely related sequences including Galβ1-4GlcNAc-
bovine serum albumin and Galβ1-4GlcNAc-bovine thy-
roglobulin. Other related carbohydrate structures including
Galβ1-4GlcNAc-, Galβ1-4Glc (lactose), Galα1-3Gal and
Galα1-6Glc (melibiose) are also ineffective targets for the
antibody [12]. Previous studies have identified this trisaccha-
ride on other murine tumor cells [18–20], but its correlation
with malignant potential had not been established.
Further studies reported here suggest that while the ter-
minal αGal is missing from carbohydrate structures on the
surface of low-malignant sarcoma cells (isolated originally
from the same tumors as the high-malignant cells), the sub-
terminal disaccharide Galβ1-4GlcNAc- is still present. This
is based on the finding that the high-malignant cells (but not
the low-malignant cells) also react with Evonymus europaea
lectin while the high- and low-malignant cells react equally
with Erythina crystagalli lectin. Evonymus europaea lectin
is similar to GS I-B4 in that it has specificity for galactose in
the α1-3 linkage but unlike GS I-B4, it does not react with
galactose in the α1-4 linkage or with N-acetyl Lactosamine
[21, 22]. Rather, Evonymus europaea has reactivity for αGal
and for fucosyl residues in certain linkages [21]. Erythina
crystagalli lectin, on the other hand, reacts with Gal β1-
4GlcNAc – the most common acceptor for the terminal αGal
[22]. The implication of these findings is that the loss or
alteration of the single, terminal monosaccharide residue
on the cell surface can have profound effects on biological
function.
What accounts for the differential expression of the
terminal αGal on the high- and low-malignant murine sar-
coma cells is not fully understood. The data presented
here demonstrate significant differences in the expression of
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α-galactosyl transferase activity which correlates with the
difference in terminal αGal expression. In contrast, there
is no significant difference in galactosidase activity and (as
indicated above) no apparent difference in expression of
the subterminal disaccharide (Gal β1-4GlcNAc-) between
the αGal expressing and non-expressing cells. Thus, it is
concluded that the differential expression of α-galactosyl
transferase activity is likely to be the major factor respon-
sible for the differences in carbohydrate profile. At present,
the molecular basis for the reduced level of α-galactosyl
transferase activity in the low-malignant cells is not known.
When steady-state mRNA levels for α1-3 galactosyl trans-
ferase were assessed in 1.0 and 1.0/anti-Br cells, no differ-
ences were seen. This could suggest a point mutation or
small deletion in the gene for this enzyme in the low ma-
lignant cells. The use of RT-PCR and nucleotide sequencing
would help to determine if this were the case. Alternatively,
a number of other explanations – post-transcriptional regu-
lation, differences in message stability or alterations in the
presence of essential co-factors or enzyme inhibitors – are
possible. Additional studies will be needed to distinguish
among these and other possibilities. These studies would
seem to be warranted, however, since the relationship be-
tween terminal αGal expression and metastatic potential has
been observed in a number of tumors, including some of
human origin [10, 11].
How differential αGal expression on the surface of
murine sarcoma cells influences tumor spread is not fully
understood. Our past studies have shown that there is no
significant difference between αGal-expressing and non-
expressing sarcoma cells in their in vitro growth rates or
saturation densities. In contrast, all of the αGal-expressing
cells are more adhesive and more motile than the Gal α1-
3-deficient cells [1, 3, 16, 23–25]. Cell-substrate adhesion
and cell motility are important for tumor invasion and metas-
tasis, and it may be that the expression of α-Gal on cell
surface glycoproteins promotes these functions. It is of in-
terest in this regard that laminin, which is a critical cell
surface component in murine tumor metastasis [26], is
glycosylated with Galα1-3Galβ1-4GlcNAc- [27]. Alterna-
tively, it has been demonstrated that αGal-non-expressing
(low-malignant) sarcoma cells are recongnized by a variety
of immunological and inflammatory cells, while the Galα1-
3-expressing (high-malignant) cells are not [28–30]. Thus,
differences in in vivo behavior between αGal-expressing-
and non-expressing cells may reflect differential interactions
with cells that have cytotoxic activity.
Of interest, while the correlation between αGal expres-
sion and malignancy appears to be absolute among murine
sarcomas, studies with murine melanoma cells provide dif-
ferent results. Specifically, it has been found that transfection
of melanoma cells with α1,3 galactosyl transferase led to
increased expression of αGal on the cell surface, and this
concomitantly reduced lung colony formation by the cells
after intravenous injection [31]. Subsequently it was shown
that the transfected cells had a reduced level of surface sialic
acid – not surprising, since galactose and sialic acid com-
pete for the same subterminal acceptor [32]. It was also
shown that capping the sub-terminal disaccharide with fu-
cose rather than galactose had a similar effect (e.g., limiting
sialic acid expression and reducing lung colony formation).
On the basis of these results, it was suggested that fail-
ure to incorporate sialic acid (rather than a positive effect
of galactose or fucose incorporation) into surface carbohy-
drates compromised capacity of the melanoma cells to carry
out one or more functions that were critical to lung colony
formation. This is consistent with past studies, which have
shown that cell membrane sialyation is positively correlated
with metastatic activity in a number of tumor models [33–
35]. How sialic acid expression influences pro-metastatic
events in melanoma cells is not fully understood. Sialic
acid-containing structures are known to serve as adhesion
ligands for leukocytes [36, 37] and expression of similar
structures on some tumor cells has been shown to correlate
with agressive behavior [38, 39]. Suffice to say in conclu-
sion that the distinctly different results with murine sarcoma
and melanoma cells attests to the fact that multiple mecha-
nisms exist for cells to carry out the necessary steps in the
metastatic process.
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